Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Xalkori (crizotinib)
pCPA File Number:
20816
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-Small Cell Lung Cancer (First Line)
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
pCODR 10054
pCPA Engagement Letter Issued:
2015-07-17
Negotiation Process Concluded:
2015-10-08